AC Immune (NASDAQ:ACIU) raised to “Buy” by StockNews.com

AC Immune (NASDAQ:ACIU – Get Free Report) was upgraded by StockNews.com from a “hold” rating to a “buy” rating in a research report issued on Monday.

A number of other brokerages also had an influence on ACIU. HC Wainwright reissued a “buy” rating and set a $16.00 target price on shares of AC Immune in a research note on Wednesday, September 18th. BTIG Research began coverage on AC Immune in a research note on Friday, May 31st. They set a “buy” rating and a $8.00 price target on the stock.

Read our latest report on ACIU

AC immune stock performance

Shares of ACIU traded down $0.03 on Monday, reaching $3.66. The company had a trading volume of 290,608 shares, compared to its average volume of 395,169. AC Immune has a 1 year low of $2.20 and a 1 year high of $5.14. The company’s fifty day moving average is $3.43 and its 200 day moving average is $3.38. The company has a market cap of $361.97 million, a P/E ratio of -5.30 and a beta of 1.24.

AC Immune (NASDAQ:ACIU – Get Your Free Report ) last posted its earnings results on Tuesday, August 6th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.42 by ($0.67). The company had revenue of $0.76 million during the quarter, compared to analysts’ expectations of $91.60 million. On average, sell-side analysts forecast that AC Immune will post -0.89 earnings per share for the current year.

Institutional trading of AC Immune

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Silverberg Bernstein Capital Management LLC acquired a new stake in AC Immune in the second quarter valued at $40,000. Lazard Asset Management LLC purchased a new stake in AC Immune in the first quarter valued at $30,000. BNP Paribas Financial Markets boosted its holdings in AC Immune by 315.6% in the first quarter. BNP Paribas Financial Markets now owns 11,092 shares of the company’s stock valued at $33,000 after purchasing an additional 8,423 shares during the last quarter. Vanguard Capital Wealth Advisors purchased a new stake in AC Immune in the second quarter valued at $56,000. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in AC Immune by 96.5% in the first quarter. China Universal Asset Management Co. Ltd. now owns 19,008 shares of the company’s stock valued at $56,000 after purchasing an additional 9,334 shares during the last quarter. 51.36% of the shares are currently owned by institutional investors and hedge funds.

About AC Immune

(Get a free report)

AC Immune SA, a clinical-stage biopharmaceutical company, discovers, designs and develops drugs and diagnostics for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies and small molecules that selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

Featured stories

Get news and reviews for AC Immune Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for AC Immune and related companies with MarketBeat.com’s FREE daily email newsletter.